SB 335 creates the Montana Dental Insurance Transparency and Accountability Act, a new framework for reporting and monitoring dental insurance “loss ratios” in Montana. The bill applies to individual and group dental insurance policies issued, renewed, or offered to Montana residents by disability insurers, but it excludes stand-alone dental coverage embedded in broader health plans subject to federal ACA medical loss ratio rules, as well as Medicaid and Healthy Montana Kids dental coverage.
The bill requires dental insurers to file annual reports with the commissioner of securities and insurance showing how premium dollars are spent, including claims, quality-improvement spending, enrollee counts, deductibles, annual maximums, and how many enrollees hit their coverage limits. The commissioner must then publish the information in a searchable public format and make insurer-specific information available on insurer websites. The bill also directs the commissioner to calculate average loss ratios by market segment, identify outlier plans, investigate low-performing insurers, and require remediation, including rebates or premium reductions, if an insurer’s dental loss ratio falls below the expected standard. It further authorizes rulemaking to define key cost categories and to address insurers whose rate increases exceed the dental services consumer price index.
In practical terms, SB 335 amends Montana insurance law by creating new transparency, reporting, and enforcement obligations for dental insurers and by carving out an exception to the state’s anti-rebate statute for rebates required under this act. It also sets a future applicability date, meaning the new requirements apply to dental policies issued or renewed on or after January 1, 2026, even though the act itself becomes effective June 1, 2025. The bill is intended to increase public visibility into premium spending and to pressure insurers to devote a larger share of premiums to patient care rather than overhead.
The overall sentiment around the bill appears generally favorable, but not unanimous. It passed the Senate with narrower margins than the House, suggesting some initial concern or skepticism in the upper chamber, while the House votes were overwhelmingly supportive. The final concurrence votes were also strong, indicating that the amended version ultimately drew broad legislative acceptance.
The main points of contention likely centered on the scope of regulation and the mechanics of the loss-ratio standard. Potential concerns include whether the commissioner should have authority to define overhead and quality-improvement spending, whether the 5% cap on quality-improvement expenditures is appropriate, and whether the bill could lead to rebates or rate constraints that affect insurer pricing and plan design. Insurers may also have been concerned about the public posting of plan-level data and the use of a statistical outlier standard to trigger enforcement and mandatory minimum loss ratios.
SB 335 adds a new chapter of Montana insurance regulation focused on dental coverage transparency and accountability. It requires annual reporting, public disclosure, commissioner review, and possible rebates or premium reductions for dental insurers whose premium spending on clinical care falls below the bill’s standards. It also amends section 33-18-208, MCA, to allow rebates required by the act notwithstanding Montana’s general prohibition on insurance rebates, and it directs the commissioner to adopt rules implementing the new reporting and enforcement framework.
The bill’s legislative history suggests broad support for the policy goal of making dental insurance spending more transparent and ensuring more premium dollars go to patient care. However, the Senate votes were relatively closer than the House votes, indicating some reservations about the regulatory approach. After amendment, the bill moved through the House and final Senate concurrence with strong majorities, showing that most lawmakers ultimately supported the measure.
The likely areas of disagreement were the bill’s regulatory reach and enforcement tools. Critics may have questioned the use of a statistical average and standard-deviation test to identify outlier insurers, the authority to mandate rebates or premium reductions, and the commissioner’s power to define what counts as clinical care, overhead, and quality-improvement spending. Insurers may also have objected to the public disclosure requirements and the 5% limit on quality-improvement expenditures, while supporters likely viewed those provisions as necessary to prevent excessive administrative spending and to protect consumers.